Target intelligence / Profile preview

Iron-sulfur cluster assembly scaffold protein ISCU (ISCU)

Target: ISCU
Molecular classification: Enzyme (scaffold protein for cofactor biosynthesis), Other (component of multi-protein biosynthetic machinery)

Overview

ISCU is a central iron-sulfur cluster assembly scaffold protein essential for synthesizing and maturing [2Fe-2S] and [4Fe-4S] clusters within mitochondria and cytosol. It coordinates the temporary formation of Fe-S clusters, which are then transferred to recipient apo-proteins by accessory proteins. The process requires precise orchestration of sulfur donation (via cysteine desulfurase such as NFS1), electron transfer (via ferredoxin and frataxin), and regulated iron availability. Fe-S clusters are crucial for the function of numerous enzymes involved in respiration, DNA repair, gene regulation, metabolism, and maintenance of cellular integrity. Defects in ISCU or other assembly components underlie mitochondrial disorders and certain neurodegenerative conditions. Although direct pharmacological targeting is limited, the Fe-S cluster assembly pathway is an emerging focus in therapeutics tied to mitochondrial health and iron metabolism.

Other names: Iron-sulfur cluster scaffold proteinISCUIron-sulfur cluster assembly scaffoldHSCB-interacting proteinFe/S cluster scaffold protein

Mechanism of action

Not drug-targeted directly. Genes and proteins that affect ISCU or Fe-S cluster assembly impact the availability and functional maturation of Fe-S cluster-containing enzymes, which drives therapeutics in related diseases

Biological functions

Cofactor biosynthesis (iron-sulfur cluster synthesis and transfer)Metabolic regulationDNA repair and genome integrityOxidative stress responseMitochondrial function

Disease associations

Neurodegenerative disease (e.g., Friedreich’s ataxia involving related assembly proteins)Mitochondrial disordersMetabolic dysfunctionOther (impaired Fe-S cluster assembly is implicated in diverse pathologies due to loss of Fe-S cluster-dependent enzyme function)

Safety considerations

Targeting ISCU or the Fe-S assembly pathway risks widespread impairment of essential mitochondrial and cytosolic enzymes, leading to multisystem dysfunction, metabolic failure, and increased oxidative cell death

Interacting drugs

None approved specifically targeting ISCU to date. Investigational agents that modulate iron metabolism or antioxidants can indirectly affect Fe-S cluster biogenesis.

Biomarkers

Decreased levels or activity of Fe-S cluster enzymes (e.g., mitochondrial aconitase, complex I/II/III of respiratory chain) in blood or tissue can indicate Fe-S cluster assembly deficiency

Beyond the preview

Go deeper on Iron-sulfur cluster assembly scaffold protein ISCU (ISCU).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iron-sulfur cluster assembly scaffold protein ISCU (ISCU).

Explore the full profile